Wall Street analysts are maintaining Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) company shares. The one year target on the name currently stands at $119.42. The stock recently touched $77.65 and has moved in the range of $75.90 - 79.81 during the current session. Based on a recent bid this places the stock +25.00% away from the 52-week floor of $62.12 and -48.83% away from the 52-week ceiling of $151.75.
When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary. Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth. Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year. Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.
K2M Group Holdings, Inc. (NASDAQ:KTWO) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $25.33 on the stock. The stock is currently trading -23.92% away from its 200-day moving average of $17.42. Based on a recent trade, shares of K2M Group Holdings, Inc. are -49.60% away from the 52-week high of $26.29 and +18.83% away from the 52-week low of $11.15.
Analysts are estimating that the company will report earnings of $-0.85 for the current year and $-0.21 for next quarter. The stock closed the most recent trading session at $12.82.
Shares of Inogen, Inc (NASDAQ:INGN) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $0.50 price target and Buy rating according to the covering analysts. During today’s session the stock hit $41.39 or +0.36% from the previous close, while moving in the range of $40.65 - 41.84.
Shares of Repligen Corporation (NASDAQ:RGEN) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $33.75 price target according to the covering analysts. During today’s session the stock hit $24.08 or +1.58% from the previous close, while moving in the range of $23.94 - 24.80. This puts the stock -42.42% away from the 52-week high of $42.48 and +21.87% away from the 52-week low of $20.07.
Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm. The consensus rating simply provides an average of those recommendations. It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
